Earlier this month, Bristol-Myers Squibb’s Opdivo picked up a new indication in the U.S.—and now, it’s keeping the momentum going with another on the other…

Mylan flatly refused to testify at a committee hearing convened by Sen. Charles Grassley, who's questioning the EpiPen maker's ultraquick Medicaid-…

Pfizer has faced scrutiny for its pricing recently, but now it’s bringing some heat of its own by suing a Texas agency to protect those numbers.

GSK has tapped a new China boss, its latest in a series of personnel changes heading into next year.

An analysis of recently launched meds holds some clues to successful—and not so successful—rollouts.

Teva is trying to clean the slate on its history of allegedly paying bribes in foreign countries and has put aside more than half a billion dollars to cover…

Celgene’s multiple myeloma growth engine Revlimid has hit a roadblock in the U.K. as it is turned away for second-line use based on value concerns.

In another sign of pharma's dwindling pricing power, Germany is on the verge of stiffening up its already strict drug pricing rules, a move that could…

Regulatory